P.2.e.001 Methylene blue for residual symptoms and for cognitive dysfunction in bipolar disorder: results of a double-blind trial

2011 ◽  
Vol 21 ◽  
pp. S417-S418 ◽  
Author(s):  
M. Alda ◽  
G.M. MacQueen ◽  
M. McKinnon ◽  
J. Garnham ◽  
S. MacLellan ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Methylene Blue ◽  
Cognitive Dysfunction ◽  
Double Blind Trial ◽  
Double Blind ◽  
Residual Symptoms ◽  
Blind Trial

A Double-Blind Trial of Budesonide Ointment and Betamethasone-17-Valerate Ointment in Psoriasis

1981 ◽  
Vol 9 (3) ◽  
pp. 236-238 ◽  
Author(s):  
H Schmidt ◽  
N Hjorth ◽  
L Salde
Keyword(s):  
Clinical Trial ◽  
Maintenance Treatment ◽  
Double Blind Trial ◽  
Double Blind ◽  
Residual Symptoms ◽  
Blind Trial

In a double-blind within-patient clinical trial in psoriasis, budesonide 0.025% ointment has been shown to be at least as efficient as betamethasone 17-valerate 0.1% ointment. A lower concentration of budesonide ointment, 0.01%, was used for 4 weeks of maintenance treatment. This concentration controlled residual symptoms well in a majority of the patients, thirty-two in number.

scholarly journals Methylene blue treatment for residual symptoms of bipolar disorder: Randomised crossover study

2017 ◽  
Vol 210 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Martin Alda ◽  
Margaret McKinnon ◽  
Ryan Blagdon ◽  
Julie Garnham ◽  
Susan MacLellan ◽  
...  
Keyword(s):  
Bipolar Disorder ◽  
Methylene Blue ◽  
Crossover Study ◽  
Rating Scale ◽  
Neuroprotective Effects ◽  
Double Blind ◽  
Residual Symptoms ◽  
Symptoms Of Depression ◽  
Hamilton Rating Scale ◽  
Active Dose

BackgroundResidual symptoms and cognitive impairment are among important sources of disability in patients with bipolar disorder. Methylene blue could improve such symptoms because of its potential neuroprotective effects.AimsWe conducted a double-blind crossover study of a low dose (15 mg, ‘placebo’) and an active dose (195 mg) of methylene blue in patients with bipolar disorder treated with lamotrigine.MethodThirty-seven participants were enrolled in a 6-month trial (trial registration: NCT00214877). The outcome measures included severity of depression, mania and anxiety, and cognitive functioning.ResultsThe active dose of methylene blue significantly improved symptoms of depression both on the Montgomery–Åsberg Depression Rating Scale and Hamilton Rating Scale for Depression (P = 0.02 and 0.05 in last-observation-carried-forward analysis). It also reduced the symptoms of anxiety measured by the Hamilton Rating Scale for Anxiety (P = 0.02). The symptoms of mania remained low and stable throughout the study. The effects of methylene blue on cognitive symptoms were not significant. The medication was well tolerated with transient and mild side-effects.ConclusionsMethylene blue used as an adjunctive medication improved residual symptoms of depression and anxiety in patients with bipolar disorder.

99: Prulifloxacin Versus Levofloxacin in the Treatment of Chronic Bacterial Prostatitis: A Prospective, Randomized, Double-Blind Trial

2007 ◽  
Vol 177 (4S) ◽  
pp. 35-35
Author(s):  
Gianluca Giannarini ◽  
Andrea Mogorovich ◽  
Girolamo Morelli ◽  
Maurizio De Maria ◽  
Francesca Manassero ◽  
...  
Keyword(s):  
Double Blind Trial ◽  
Chronic Bacterial Prostatitis ◽  
Double Blind ◽  
Blind Trial ◽  
Bacterial Prostatitis
Sign in / Sign up

Export Citation Format

Share Document